Pfizer Plans For COVID Transition And RSV Vaccine Launch
Executive Summary
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.
You may also be interested in...
From Hallelujah To Headwind: Pfizer's COVID-19 Franchise Hits The Downturn
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.
Pfizer’s COVID-19 Franchise Dominates Best-Seller List
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
BioNTech Beefs Up AI/ML Investment With InstaDeep Buy
The company is spending up to £562m to acquire artificial intelligence/machine learning provider InstaDeep, which it has partnered with since 2020, as competitor Moderna has made digital technology a cornerstone of its strategy.